Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research

Abstract

Despite surgical resection and adjuvant chemoradiation, survival for glioblastoma remains poor. Because of the dismal prognosis, attention has shifted to alternative adjuvant treatment modalities. Although traditionally limited to systemic malignancies (melanoma, lung and colon cancer), the field of immunotherapy has recently identified glioblastoma as a potential target for new treatments. Anti-tumor vaccines (dendritic cell/heat shock), checkpoint inhibitors, chimeric T-cell receptors, and virotherapy all have been preliminarily trialed in glioblastoma patients with reasonable success and safety. Although there are certainly limitations due to autoimmune reactions and immune escape, immunotherapeutics hold much promise in the future treatment paradigms for malignant glioma.

Keywords:

• Immunotherapy
• Glioblastoma
• Novel
• Outcomes
• Clinical trial

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.